Uterine anomalies in pregnancy

Publication
Article
Contemporary OB/GYN JournalVol 67 No 12
Volume 67
Issue 12

Clinical pearls for assessment and management of the pregnant patient with a uterovaginal anomaly.

View as PDF

Uterine anomalies are associated with higher rates of pregnancy complications, including spontaneous abortion, ectopic pregnancy, preterm labor, malpresentation, and abruption. Obstetricians should understand the embryology, incidence, classifications, and management of patients with uterine anomalies during pregnancy.

Embryology

The process of uterine and vaginal development begins in the first trimester. The bilateral müllerian (paramesonephric) ducts develop into the uterus, fallopian tubes, cervix, and proximal vagina. These ducts fuse and internal canalization of each duct will produce 2 channels divided by longitudinal septum. The septum will typically resorb throughout the second trimester. The urogenital sinus will also separate into the distal vagina and urethra. Resorption anomalies represent persistence of the longitudinal uterine or vaginal septum. Transverse anomalies include obstructing vaginal septa or
cervical atresia.

Classification and diagnosis of uterovaginal anomalies

The American Society for Reproductive Medicine (ASRM) Müllerian Anomalies Classification (MAC) system, updated in 2021,1 categorizes the range of anomalies by descriptive terms and includes müllerian agenesis, cervical agenesis, unicornuate uterus, uterus didelphys, bicornuate uterus, septate uterus, longitudinal vaginal septum, transverse vaginal septum, and complex anomalies. An online interactive classification is available online. To view the ASRM MAC 2021 online, please scan the QR code.

Diagnosis

To differentiate uterine anomalies, imaging or direct visual examination of the contour of external uterus and the endometrial cavity is required. To differentiate the bicornuate from septate from arcuate uterus, ideally, a line can be drawn from cornua to cornua. If the external contour indents more than 10 mm, the uterus is bicornuate. If there is less than 10-mm external contour indentation and less than a 10-mm fundal cavitary indentation with the leading angle of the indentation greater than 90°, the diagnosis is arcuate uterus. If the indentation extends more than 10 mm into the cavity and the leading angle is less than 90°, the diagnosis is septate uterus.

Optimal tests include 3D transvaginal ultrasound, MRI, saline sonohysterography, or laparoscopy or laparotomy combined with hysteroscopy or hysterosalpingogram (HSG; Figures 1 and 2).2,3 Less sensitive diagnostic tests include 2D transvaginal ultrasound, clinical assessment at cesarean section, as well as hysteroscopy or HSG without external uterine contour evaluation.4 A pregnancy will alter the contour of the uterine fundus and repeat imaging after resolution of the pregnancy is more likely to result in an accurate diagnosis.

FIGURE 1. MRI images allow visualization of the patent and nonpatent uterine anatomy. This image is diagnostic for a left unicornuate uterus with patent vagina (outlined arrow) and a functional right noncontiguous uterine horn (solid arrow).2,3 (Image courtesy of Anne-Marie Amies Oelschlager, MD.)

FIGURE 1. MRI images allow visualization of the patent and nonpatent uterine anatomy. This image is diagnostic for a left unicornuate uterus with patent vagina (outlined arrow) and a functional right noncontiguous uterine horn (solid arrow).2,3 (Image courtesy of Anne-Marie Amies Oelschlager, MD.)

FIGURE 2. A complete septate uterus. The arrow points to the septum at the level of the internal os of the cervix. The septum extends into the cervix. Note that the leading angle of the septum in the endometrial cavity is less than 90°, and there is a flat external fundal contour.2,3 (Image courtesy of Anne-Marie Amies Oelschlager, MD.)

FIGURE 2. A complete septate uterus. The arrow points to the septum at the level of the internal os of the cervix. The septum extends into the cervix. Note that the leading angle of the septum in the endometrial cavity is less than 90°, and there is a flat external fundal contour.2,3 (Image courtesy of Anne-Marie Amies Oelschlager, MD.)

Incidence and associated anomalies

Studies using optimal imaging have identified uterine anomalies in
5.5% to 9.8% of the general population, in 16.7% of those with recurrent miscarriage, and in 24.5% of those with a history of miscarriage and infertility.5-8 A study of uterine evaluation during cesarean sections noted that 5% were found to have a uterine anomaly: 71.0% were septate uteri, 19.4% were bicornuate uteri, 6.4% were unicornuate uteri, and 3.2% were didelphic uteri.4

Anorectal, cardiac, limb, ear, skeletal, and especially renal anomalies have all been commonly associated with müllerian anomalies. Obstetricians should have a low threshold to consider renal imaging, as they may be present in
30% of those with fusion anomalies.9,10

Obstetric complications

Arcuate uterus is the most common anomaly identified, but it does not appear to be associated with a higher rate of infertility or miscarriage by prospective studies.5,11 In general, the arcuate uterus is considered a benign variant; however, the remaining uterine anomalies confer a significantly higher risk of obstetric complications. The incidence of preterm birth before
37 weeks is approximately 40% for patients with known uterine anomalies. The highest risk of preterm labor is associated with uterine didelphys (56%), unicornuate uterus (43%), bicornuate uterus (39%), and septate uterus (31%).12 Congenital uterine anomalies are also associated with increased risk of first and second trimester loss, cervical insufficiency, premature rupture of membranes, fetal malpresentation, fetal growth restriction, placental abruption, placenta previa, retained placenta, and cesarean birth
(Table).13-15 For this reason, consultation with a maternal-fetal medicine specialist during pregnancy is recommended.

Management of obstetric risk

Limited data suggest that cervical length screening for short cervix (< 25 mm) and fetal fibronectin screening may be useful for predicting preterm birth in those with septate uteri. The data have not shown a consistent predictive benefit for those with unicornuate, didelphic, or bicornuate uteri.16,17

Most studies of 17-hydroxyprogesterone caproate (17-OHPC) for prevention of premature birth did not include those with a history of congenital uterine anomalies. In a small retrospective cohort study of 48 women with congenital uterine anomalies, there was an equally high rate of recurrent preterm birth in those who received 17-OHPC and those who did not. 17-OHPC has not been demonstrated to prolong pregnancy in women with uterine malformations or prenatal diethylstilbestrol exposure.18

Patients with a history of cervical atresia may have had reconstructive surgery to create a patent cervix. In those who can become pregnant, case reports have suggested that abdominal cerclage with planned cesarean delivery is warranted.19 There are limited data to suggest that cerclage may decrease the rate of preterm delivery in those with bicornuate uteri with cervical incompetence.20

Historically, hysteroscopic uterine septum resection has been recommended for those with a history of recurrent pregnancy loss, preterm labor, and infertility.21 In case control studies, hysteroscopic metroplasty has been associated with a higher live birth rate and lower spontaneous abortion rate but has also been associated with higher rates of preterm delivery, cesarean section, and fetal malpresentation compared with those with uterine septum who did not have surgery.22,23

A multinational multicenter trial randomly assigned 80 women with a septate uterus to septum resection or expectant management. Live births occurred in 31% who had septum resection compared with 35% who did not have surgery.24 It appears that uterine septum resection may benefit select patients with recurrent fetal loss, but their risk of obstetric complications is still significantly elevated. If the septum extends into the cervix, resection of the cervical component has not been typically recommended due to concern for an increased risk of cervical incompetence.

Delivery considerations

The incidence of cesarean delivery in those with uterine anomalies is significantly higher, likely because of a combination of higher rates of abruption, preterm labor, and malpresentation. The risks of abruption and failure of external cephalic version (ECV) may be higher in patients with uterine anomalies; however, there have been case reports of successful ECV.25

If a longitudinal vaginal septum is identified during a pregnancy, the septum can be resected prior to labor in the operating room or during the first stage or early second stage of labor prior to pushing. Clamping and resecting the intervening septal tissue should be done with extreme care to avoid the bowel, urethra, and the cervices. Use of the LigaSure device (Medtronic) has also been described.26 After vaginal delivery, the vagina should be carefully inspected, hemostasis assured, and gaps in the mucosa should be reapproximated using absorbable suture.27

Many patients with obstructive uterovaginal anomalies will present in adolescence or prior to puberty. Some patients may have had vaginal septum resection for a transverse vaginal septum or may have had a vaginal pull-through procedure for distal vaginal atresia. Interposition vaginal grafts, including buccal mucosa or bowel grafts, may have been used to bridge the gap between the upper and lower vagina.

In these situations where interposition grafts or residual septal tissue is present, and there is a concern for vaginal obstruction, planned cesarean delivery is recommended. Additionally, for those who have had anorectal malformations with a history of anoplasty or reconstructive urological procedures where continence may be negatively impacted by vaginal delivery, planned cesarean delivery should be offered. For any patient with a uterovaginal anomaly, aberrant urologic anatomy, including pelvic kidneys and ectopic and duplicate ureters, are common. Obstetricians should be vigilant during operative deliveries to avoid injury to the urinary system.

Obstetricians should be prepared for an increased rate of retained placenta after vaginal delivery in patients with uterine anomalies. Ultrasound-guided management of instrumentation during removal of retained placental tissue is recommended

Management of therapeutic and spontaneous abortion

For those with 2 cervices, a history of vaginal septum resection, or long interposition vaginal grafts, uterine evacuation can be challenging, with increased difficulty visualizing and dilating 1 or both cervices. For those with a uterine septum, bicornuate uterus, or uterine didelphys, care must be taken to avoid inadvertent instrumentation of the wrong cervix and uterine horn. For those with congenital reproductive tract anomalies, procedures should be performed with ultrasound guidance.28 Operative hysteroscopy may facilitate guided entry into the cavity if dilation with ultrasound guidance alone is not successful.29 Although rare, there are case reports of ectopic pregnancies occurring in asymmetric or noncommunicating uterine horns. MRI may be useful if a pregnancy is visualized by ultrasound but is not accessible through uterine instrumentation and cannot be visualized through hysteroscopy.30

Conclusion

Uterine anomalies are common in the general population and are associated with a higher risk of obstetric complications. Optimal imaging is recommended for accurate diagnoses. Consultation with a maternal-fetal medicine specialist is recommended during pregnancy.

____

References

  1. Pfeifer SM, Attaran M, Goldstein J, et al. ASRM müllerian anomalies classification 2021. Fertil Steril. 2021;116(5):1238-1252. doi:10.1016/j.fertnstert.2021.09.025
  2. Kougioumtsidou A, Mikos T, Grimbizis GF, et al. Three-dimensional ultrasound in the diagnosis and the classification of congenital uterine anomalies using the ESHRE/ESGE classification: a diagnostic accuracy study. Arch Gynecol Obstet. 2019;299(3):779-89. doi:10.1007/s00404-019-05050-x
  3. Imboden S, Müller M, Raio L, Mueller MD, Tutschek B. Clinical significance of 3D ultrasound compared to MRI in uterine malformations. Ultraschall Med. 2014;35(5):440-444. doi:10.1055/s-0033-1335664
  4. Mohamed MA, AbdelRahman MY. Frequency and types of uterine anomalies during caesarean section. J Obstet Gynaecol. 2019;39(2):147-150. doi:10.1080/01443615.2018.1499712
  5. Chan YY, Jayaprakasan K, Zamora J, Thornton JG, Raine-Fenning N, Coomarasamy A. The prevalence of congenital uterine anomalies in unselected and high-risk populations: a systematic review. Hum Reprod Update. 2011;17(6):761-771. doi:10.1093/humupd/dmr028
  6. Dreisler E, Stampe Sørensen S. Müllerian duct anomalies diagnosed by saline contrast sonohysterography: prevalence in a general population. Fertil Steril. 2014;102(2):525-529. doi:10.1016/j.fertnstert.2014.04.043
  7. Saravelos SH, Cocksedge KA, Li TC. Prevalence and diagnosis of congenital uterine anomalies in women with reproductive failure: a critical appraisal. Hum Reprod Update. 2008;14(5):415-429. doi:10.1093/humupd/dmn018
  8. Jaslow CR, Kutteh WH. Effect of prior birth and miscarriage frequency on the prevalence of acquired and congenital uterine anomalies in women with recurrent miscarriage: a cross-sectional study. Fertil Steril. 2013;99(7):1916-22.e1. doi:10.1016/j.fertnstert.2013.01.152
  9. Acién P, Acién M, Mazaira N, Quesada-Rico JA. Reproductive outcome in uterine malformations with or without an associated unilateral renal agenesis. J Reprod Med. 2014;59(1-2):69-75.
  10. Heinonen PK. Pregnancies in women with uterine malformation, treated obstruction of hemivagina and ipsilateral renal agenesis. Arch Gynecol Obstet. 2013;287(5):975-978. doi:10.1007/s00404-012-2680-0
  11. Prior M, Richardson A, Asif S, et al. Outcome of assisted reproduction in women with congenital uterine anomalies: a prospective observational study. Ultrasound Obstet Gynecol. 2018;51(1):110-117. doi:10.1002/uog.18935
  12. Hua M, Odibo AO, Longman RE, Macones GA, Roehl KA, Cahill AG. Congenital uterine anomalies and adverse pregnancy outcomes. Am J Obstet Gynecol. 2011;205(6):558.e1-558.e5585. doi:10.1016/j.ajog.2011.07.022
  13. Kim MA, Kim HS, Kim YH. Reproductive, obstetric and neonatal outcomes in women with congenital uterine anomalies: a systematic review and meta-analysis. J Clin Med. 2021;10(21):4797. doi:10.3390/jcm10214797
  14. Takami M, Aoki S, Kurasawa K, Okuda M, Takahashi T, Hirahara F. A classification of congenital uterine anomalies predicting pregnancy outcomes. Acta Obstet Gynecol Scand.2014;93(7):691-697. doi:10.1111/aogs.12400
  15. Panagiotopoulos M, Tseke P, Michala L. Obstetric complications in women with congenital uterine anomalies according to the 2013 European Society of Human Reproduction and Embryology and the European Society for Gynaecological Endoscopy classification: a systematic review and meta-analysis. Obstet Gynecol. 2022;139(1):138-148. doi:10.1097/AOG.0000000000004627
  16. Hughes KM, Kane SC, Haines TP, Sheehan PM. Cervical length surveillance for predicting spontaneous preterm birth in women with uterine anomalies: a cohort study. Acta Obstet Gynecol Scand. 2020;99(11):1519-1526. doi:10.1111/aogs.13923
  17. Ridout AE, Ibeto LA, Ross GN, et al. Cervical length and quantitative fetal fibronectin in the prediction of spontaneous preterm birth in asymptomatic women with congenital uterine anomaly. Am J Obstet Gynecol. 2019;221(4):341.e1-341.e9. doi:10.1016/j.ajog.2019.05.032
  18. Hynes JS, Schwartz AR, Abdalla A, Manuck TA, Dotters-Katz SK. 17-hydroxyprogesterone caproate for women with congenital uterine anomalies: does it impact the risk of recurrent preterm birth? Am J Obstet Gynecol MFM. 2021;3(1):100278. doi:10.1016/j.ajogmf.2020.100278
  19. Schaible B, Haught E, Vozar A, et al. Abdominal cerclage in a patient with a neocervix with planned cesarean hysterectomy at delivery. J Obstet Gynaecol Res. 2021;47(1):416-419. doi:10.1111/jog.14525
  20. Yassaee F, Mostafaee L. The role of cervical cerclage in pregnancy outcome in women with uterine anomaly. J Reprod Infertil. 2011;12(4):277-279.
  21. Hickok LR. Hysteroscopic treatment of the uterine septum: a clinician’s experience. Am J Obstet Gynecol. 2000;182(6):1414-1420. doi:10.1067/mob.2000.106130
  22. Loddo A, D’Alterio MN, Neri M, Masala F, Cane FL, Melis GB. Pregnancy complications after hysteroscopic metroplasty: a ten-year case-control study. Surg Technol Int. 2017;30:205-209.
  23. Carrera M, Pérez Millan F, Alcázar JL, et al. Effect of hysteroscopic metroplasty on reproductive outcomes in women with septate uterus: systematic review and meta-analysis. J Minim Invasive Gynecol. 2022;29(4):465-475. doi:10.1016/j.jmig.2021.10.001
  24. Rikken JFW, Kowalik CR, Emanuel MH, et al. The randomised uterine septum transsection trial (TRUST): design and protocol. BMC Womens Health. 2018;18(1):163. doi:10.1186/s12905-018-0637-6
  25. Mirzai S, Wolf SB, Mili S, Rifai AO. Successful external cephalic version in a patient with uterus didelphys and fetal malpresentation. BMJ Case Rep. 2019;12(11):e230965. doi:10.1136/bcr-2019-230965
  26. Perez-Milicua G, Hakim J, Adeyemi O, Dietrich JE. Longitudinal vaginal septum resection using the Ligasure device. J Pediatr Adolesc Gynecol. 2016;29(6):e95-e96. doi:10.1016/j.jpag.2016.06.002
  27. de França Neto AH, Nóbrega BV, Clementino Filho J, do Ó TC, de Amorim MM. Intrapartum diagnosis and treatment of longitudinal vaginal septum. Case Rep Obstet Gynecol. 2014;2014:108973. doi:10.1155/2014/108973
  28. Rubin ES, Huttler A, Mainigi M, Roe AH. Surgical uterine evacuation in patients with two cervices: a case series. Contraception. 2022;108:73-77. doi:10.1016/j.contraception.2022.01.001
  29. Ryu S, Baek HW, Lee I, et al. Operative hysteroscopy-assisted pregnancy termination after failed surgical abortion in missed abortion of woman with complete septate uterus. Obstet Gynecol Sci. 2020;63(1):102-106. doi:10.5468/ogs.2020.63.1.102
  30. Liu Y, Wang S, Hong Y, et al. Pregnancy in the blind hemi-cavity of Robert’s uterus: a case report. Radiol Case Rep. 2021;16(5):1085-1088. doi:10.1016/j.radcr.2021.02.013
© 2024 MJH Life Sciences

All rights reserved.